Circulating levels of vascular endothelial markers in obstructive sleep apnoea syndrome. Effects of nasal continuous positive airway pressure

Abstract

Introduction

Obstructive sleep apnoea syndrome (OSAS) is an important risk factor in cardiovascular disorders. Although the exact mechanism remains to be elucidated, the endothelial dysfunction process seems to be implicated.

Material and methods

In order to test this hypothesis, blood circulating levels of endothelial markers were measured at baseline and 1 year after treatment with continuous positive airway pressure (CPAP). We studied 37 males using polysomnography: 20 subjects with OSAS and a 17-subject control group. An OSAS-validated sleep questionnaire covering the most important cardiovascular risk factors was applied to all subjects. Furthermore, patients received a complete general physical examination and biochemistry test with lipid profile. The specific markers measured were intercellular cell adhesion molecule-1 (ICAM-1), E-selectin, endothelin-1, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1).

Results

Obstructive sleep apnoea syndrome patients presented higher circulating levels of ICAM-1, endothelin-1 and PAI-1 than the control group. On the other hand, no differences were found in E-selectin and vWF. After 1 year of CPAP treatment, there was a significant decrease in circulating levels of ICAM-1 and PAI-1. On the other hand, no differences were found in endothelin-1, E-selectin and vWF.

Conclusions

Obstructive sleep apnoea syndrome is associated with elevated levels of ICAM-1 and PAI-1 and these levels normalize after treatment with CPAP.

Introduction

Obstructive sleep apnoea syndrome (OSAS) is a respiratory disorder characterized by recurrent airflow obstruction caused by total or partial collapse of the upper airway. Obstructive sleep apnoea syndrome is a common disorder [1], with important consequences such as deterioration of quality of life [2] and more frequent automobile accidents [3]. Obstructive sleep apnoea syndrome has been associated with hypertension and cardiovascular disease [4] and a number of studies have shown that this cardiovascular risk decreases after continuous positive airway pressure (CPAP) treatment [5, 6].

Increased sympathetic activity and hypoxia associated with apnoeic episodes has been proposed as a possible mechanism to explain the association between OSAS and cardiovascular disease [7]. Continuous positive airway pressure treatment may lower cardiovascular risk by reducing sympathetic nerve activity, ambulatory blood pressure and arterial stiffness and by increasing sensitivity of the arterial baroreflex [8, 9].

Obstructive sleep apnoea syndrome-induced hypoxic stress increases circulating inflammatory mediators leading to cardiovascular lesions [10, 11], which in turn may lead to endothelial dysfunction. Endothelial dysfunction is an early marker of vascular abnormality preceding clinically overt cardiovascular disease [12]. It is known that endothelial dysfunction identified in the peripheral vasculature strongly predicts coronary disease [13]. A number of studies involving OSAS patients indicate an associated endothelial dysfunction [14, 15] that improves after CPAP [16, 17].

An imbalance of the coagulation/fibrinolysis axis may also exist. Hypercoagulability resulting from increased coagulation or inhibited fibrinolysis is associated with an increased risk of atherothrombotic disease and cardiovascular disease [18, 19]. A prothrombotic state has been associated with increased risk of coronary artery disease [20] and is a possible link between OSAS and cardiovascular disease [21]. Although most of the above-mentioned OSAS-related physiopathological consequences return to normal after CPAP treatment, the results reported in the literature have not been consistent. The reason may be that these studies do not exclude other cardiovascular risk factors and that their analysis of markers is too limited.

The aim of the present study was to measure circulating ICAM-1, E-selectin, endothelin-1, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) in OSAS patients before CPAP treatment at 1-year follow-up.

Material and methods

Subjects

The present study included 20 male subjects, 33 to 64 years of age (mean of 49.9 ±8.9 years), with a mean apnoea-hypopnoea index (AHI) of 45.2 ±26.2 and body mass index (BMI) of 29.9 ±4.6 kg/m², diagnosed with OSAS after performing polysomnography studies. A control group made up of 17 male subjects from the general population was also included. Exclusion criteria were previous treatment for OSAS, chronic obstructive lung disease, vascular disease, history of hypertension, diabetes mellitus, and chronic renal illness.

The Review Board on Human Studies at our institution approved the protocol, and each patient gave his or her informed consent to participate in the study.

Interventions

An OSAS-validated sleep questionnaire covering the most important cardiovascular risk factors was applied to all subjects. Furthermore, patients received a complete general physical examination, biochemistry test with lipid profile and polysomnographic tests.

Polysomnographies were carried out in our Sleep Unit usually from midnight to 8 a.m. This technique consisted of continuous monitoring using a polygraph (Ultrasom Network, Nicolet, Madison, Wi, USA) and included electroencephalogram, electro-oculogram, chin electromyogram, airflow, electrocardiogram and measurement of chest wall movement. The polysomnographic register was analysed in periods of 30 s and during stages 1, 2, 3, 4 and REM according to standard criteria.

Apnoea was defined as the absence of airflow for more than 10 s, and hypopnoea as 50% reduction of respiratory flow for at least 10 s resulting in an arousal or a decrease of 4% in the oxygen saturation of haemoglobin

The average apnoea-hypopnoea index (AHI) was calculated in hourly samples of sleep. In this study an AHI ≥ 10 was considered as diagnostic of OSAS. If the subject had less than 3 hours of total sleep, the sleep study was repeated.

The optimal CPAP level was determined in the laboratory during the study. It was defined as the combination of the lowest pressure, lowest number of respiratory events and arousals, and the highest sleep efficiency.

Endothelial markers

Whole blood was obtained by venipuncture in all subjects between 8 a.m. and 10 a.m. after polysomnographic study.

A total of 5 endothelial dysfunction markers were measured: ICAM-1, E-selectin, endothelin-1, vWF, PAI-1. The blood samples were centrifuged at 1000 g for 10 min, and serum/plasma was frozen and stored at −20°C.

Commercially available enzyme-linked immunosorbent assay (ELISA) methods were used to determine serum levels of ICAM-1 and soluble E-selectin (R&D Systems, Minneapolis, USA), EDTA-plasma levels of endothelin-1 (Biomedica, Wien, Austria), and citrated plasma levels of vWf and PAI-1 (Diagnostica Stago, Asnieres, France).

The mean minimal detectable level was determined by adding two standard deviations to the mean optical density value of 20 zero standard replicates and calculating the corresponding concentrations.

Follow-up protocol

Serum/plasma levels of endothelial markers were measured at baseline and 1 year after CPAP treatment. Patient interviews were conducted by a study-team member who was not aware of the patient's AHI status and did not participate in any other aspects of clinical management. No interventions other than CPAP therapy were introduced at follow-up. Referring physicians were permitted to modify general medical therapy as required. All patients received standardized instructions by Sleep Center staff and by a home health care provider at the start of CPAP treatment. Patients were reviewed at the Sleep Clinic at 1, 6, and 12 months or when any problem with the CPAP device or mask fit was encountered. In addition, patients were reviewed every 2 months by a home health care provider.

Continuous positive airway pressure compliance

The total time that CPAP units were switched on was logged using the unit time clock. A home health care provider registered these compliance measures. Each time the patient was visited, the number of hours logged on the meter was recorded and the CPAP device was given a maintenance check.

Continuous positive airway pressure satisfaction scale

At 12-month follow-up, patients were asked to rank CPAP treatment on a scale from 0 (‘‘no effect at all’’) to 10 (‘‘complete relief of symptoms’’).

Data analysis and measurements

Continuous variables are expressed as mean±standard deviation, or as median (percentile 25, percentile 75). The t-test, two tailed for paired samples, was applied to test differences pre- and post-treatment; non-normally distributed variables were compared using Wilcoxon rank sum test for paired data. Statistical significance was accepted at p < 0.05. All analyses were developed using the Statistical Package for Social Sciences (SPSS, version 15.0; SPSS Inc. Chicago, IL, USA).

Results

Baseline clinical characteristics of patients and control subjects were similar for age, body mass index (BMI), smoking habit and blood pressure (Table I).

Table I. Cardiovascular risk factors in control and OSAS groups

Variable	Control group (n=18)	OSAS group (n=20)	Value of p
Age [year]	44.1 (14.2)	50.1 (8.9)	0.12
Smokers, n (%)	5 (27)	8 (40)	0.364
BMI [kg/m2]	27.6 (3.1)	29.9 (4.6)	0.078
SBP [mmHg]	124 (7.3)	128 (11)	0.156
DBP [mmHg]	79.7 (11.4)	78.5 (10.5)	0.734

BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, data are expressed as mean (SD)

After 12 months of nasal CPAP treatment, 82% of patients reported that they had used nasal CPAP every day for more than 5 h per night. The CPAP titration pressure ranged from 5 cm H₂O to 14 cm H₂O (mean=7.8 ±1.51 cm H₂O). On average, CPAP was used for 5.24 ±2.75 h per night. Patients self-reported a level of satisfaction of 7.48 ±1.90 points after the CPAP treatment.

Table II describes circulating endothelial markers. Levels of ICAM-1, E-selectin and endothelin-1 were significantly elevated in OSAS patients as compared to controls. After treatment we can see a significant decrease in ICAM-1 and PAI, but not in endothelin, E-selectin, or vWF.

Table II. Plasma levels of vascular endothelial markers in control and OSAS group at baseline and after 1 year of CPAP treatment

Variable	Control group (n=18)	OSAS group (n=20)	Value of p	After CPAP (n=20)	Value of p
ICAM-1 [ng/ml]	218 (190, 255)	261 (200, 294)	0.050	229 (182, 270)	0.022
E-selectin [ng/ml]	54 (45, 63)	66 (48, 90)	0.143	72 (42, 93)	0.234
Endothelin [fmol/ml]	0.2 (0.12, 0.30)	0.35 (0.26, 0.45)	0.003	0.35 (0.26, 0.40)	0.722
vWF [%]	76 (63, 91)	83 (65, 100)	0.411	79 (65, 101)	0.616
PAI-1 [ng/ml]	30 (18, 45)	52 (24, 72)	0.027	37 (12, 53)	0.020

BMI – body mass index, AHI – apnoea-hypopnoea index, ICAM – intercellular adhesion molecule 1, vWF – von Willebrand factor, PAI – plasminogen activator inhibitor-1, data are medians and 25^th-75^th percentile ranges (within parentheses)

Discussion

The present study demonstrates that endothelial dysfunction, represented by changes in certain circulating endothelial markers, is present in OSAS. We found that treating OSAS patients with CPAP reduced levels of ICAM-1 and PAI-1. On the other hand, no changes were found in endothelin, Von Willebrand factor and E-selectin.

The intact endothelium regulates vascular tone and repair capacity, maintaining proinflammatory, anti-inflammatory, and coagulation homeostasis. Endothelial dysfunction is characterised by an increase in vasoconstrictive substances, such as endothelin, and activation of adhesion molecules, such as ICAM-1 and E-selectin [22]. Alteration of these homeostatic pathways results in endothelial dysfunction before structural changes in the vasculature.

The association of endothelial function with OSAS observed in our study is consistent with other studies showing an association between OSAS and other markers of endothelial dysfunction, such as circulating levels of adhesion molecules [23], and vascular endothelial growth factor [24]. Furthermore, these changes improve after CPAP therapy [23, 24].

In a previous study, we found that OSAS patients compared to a control group had increased levels of ICAM-1, and that this could be due to OSAS-induced hypoxia [25]. Low oxygen tension is a trigger for activation of polymorphonuclear neutrophils, which adhere to the endothelium. El-Solh et al. observed that both were significantly correlated with the oxygen desaturation index, thus suggesting that expression of adhesion molecules might be related to the intermittent hypoxia observed during sleep [26]. In fact, in vitro studies involving perfused cell cultures have shown that hypoxia/reoxygenation causes an increase in the levels of adhesion molecules [27].

The hypoxia, hypercapnia, and arterial pressure surges accompanying obstructive apnoeic events may serve as potent stimuli for the release of vasoactive substances and for impairment of endothelial function [28, 29].

A variety of findings support the existence of a relation between hypercoagulability, OSAS and cardiovascular disease. Firstly, patients with OSAS present higher plasma levels of several procoagulant factors such as fibrinogen [30], platelet activity [31], and PAI-1 [32, 33]. Secondly, increased D-dimer levels in untreated OSAS have been correlated with severity of nocturnal hypoxemia, characteristic of OSAS [34]. Thirdly, sleep fragmentation and sleep efficiency data have been associated with increased levels of vWF and soluble tissue factor (sTF), two markers of a prothrombotic state [35].

In OSAS, surges in sympathetic nervous system activity associated with apnoeic events have also been related to anti-fibrinolytic activity reflected by elevations of PAI-1 [21, 36]. In a previous study, we also found that patients with OSAS presented significantly higher circulating levels of PAI-1, and the difference was even more marked in patients with both OSAS and hypertension [32]. In the current study, treatment with CPAP decrease blood levels of PAI-1.

Among the most important vasoconstrictive substances is endothelin-1, a peptide hormone secreted under the influence of hypoxia [37, 38]. However, the evidence for increased production of vasoconstrictive substances such as endothelin-1 in patients with OSAS is inconsistent. Several studies have reported higher endothelin-1 levels in OSAS patients [25, 39, 40]; however, Grimpen reports conflicting findings [41]. This divergence might be explained by differences in study design. The groups studied by Phillips et al. [39] and Saarelainen and Hasan [40] had more severe disease and thus underwent more severe oxygen desaturations that acted as a trigger for endothelin-1 secretion. Gjo/rup showed that hypertensive OSAS patients had greater nocturnal and diurnal endothelin-1 plasma levels than healthy controls, suggesting that OSAS does not affect plasma endothelin-1 levels in the absence of coexistent cardiovascular diseases [42, 43].

The inconsistency of the above endothelin-1 levels likely reflects the predominantly abluminal release of endothelin. Using rat models of arterial hypertension, several authors have reported elevated vascular production of endothelin-1, while circulating levels remained similar to controls [44, 45]. This demonstrates that circulating levels of endothelin-1 do not exclude elevated vascular production in OSAS. Our findings indicate that the control of apnoeas through CPAP treatment did not modify initial levels of endothelin.

Certain limitations in the present study need to be taken into consideration. Firstly, the measurements of circulating adhesion molecules were based on the assumption that the number of circulating adhesion molecules reflects the number of cell surface adhesion molecules. Secondly, blood samples were obtained only in the morning, which may have affected random variability because oscillations during the day were not taken into account.

In conclusion, as a follow-up to our previous findings regarding the increased levels of adhesion molecules and PAI-1 associated with OSAS, here we demonstrate that levels of these markers return to normal with long-term CPAP treatment.